TB treatment

TB treatment features

• 

  HIV and TB in Practice for nurses: Pregnancy and TB/HIV

  This article explains how to prevent and treat TB in pregnant women to protect both mother and child....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: Drug-resistant TB

  This article summarises the key recommendations on the diagnosis and treatment of drug-resistant TB for nurses, and highlights examples of best practice in their care....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses: Starting ART for treatment and prevention in people with active TB and HIV

  This article provides information for nurses on starting HIV treatment for people with HIV and active TB....

  From:  HIV & AIDS treatment in practice

• 

  TB, HIV, mothers and children: time for action

  This year’s World TB Day edition of HATIP focusses on the needs of pregnant women and children with TB....

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice for nurses

  This is the first of a special monthly edition of HATiP for nurses and other health care workers involved in task-shifting in sub-Saharan Africa....

  From:  HIV & AIDS treatment in practice

• 

  Managing MDR-TB in the community: from presentation to cure or end-of-life care

  Part of a series, this edition examines the sequence of care of a person with drug-resistant TB. ...

  From:  HIV & AIDS treatment in practice

• 

  Decentralised, patient-centred models of delivering treatment and palliative care for people with M/XDR-TB

  Part of a series on improving care of multidrug-resistant tuberculosis, this edition examines delivery of treatment and palliative care, focusing on decentralised patient-centred TB care....

  From:  HIV & AIDS treatment in practice

• 

  HIV & TB in Practice: Improving clinical management of TB in people with HIV

  “If HIV and tuberculosis (TB) are both treatable diseases, why do some patients with HIV-associated TB require hospital admission and die?” asked Dr Graeme Meintjes,...

  From:  HIV & AIDS treatment in practice

• 

  WHO issues updated TB treatment guidelines

  Treatment regimens for tuberculosis should include an antibiotic of the rifamycin class for the full six months of therapy, according to new World Health Organization...

  From:  HIV & AIDS treatment in practice

• 

  HIV and TB in Practice

  This articles looks at the issue of isoniazid resistance in isoniazid preventive therapy (IPT) and TB programmes. ...

  From:  HIV & AIDS treatment in practice

TB treatment in your own words

• 

  TB - my experiences

  This might sound odd, but I was really shocked when I became seriously ill because of HIV. I was even more shocked when it turned...

  From:In your own words

TB treatment news from aidsmap

• Dosing of key TB drug rifampicin could go higher

  Rifampicin, a key drug in tuberculosis (TB) treatment, can be tolerated at much higher doses than used in current clinical practice – suggesting that much higher drug levels may lead to a more rapid treatment response, allowing the treatment ...

  07 March 2013 | Keith Alcorn

• Once-weekly continuation phase TB treatment equals standard of care

  A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis (TB) treatment to be taken once-weekly during the four-month continuation phase, Dr Amina Jindani of St George’s University Medical School, London, told the 20th Conference on Retroviruses and ...

  07 March 2013 | Keith Alcorn

• FDA Advisory Committee recommends accelerated approval of bedaquiline for drug-resistant TB

  Bedaquiline, the first agent in a new class of TB drug, has been recommended for accelerated approval by the Anti-Infective Drugs Advisory Committee of the United States Food and Drug Administration (FDA). The committee voted unanimously (18 to 0) ...

  03 December 2012 | Lesley Odendal

• Risk of recurrence of active TB is high for people with HIV

  People living with HIV who have a history of active tuberculosis (TB) have a significant risk of the recurrence of the disease, investigators report in the online edition of Clinical Infectious Diseases. The risk of developing active TB ...

  22 October 2012 | Michael Carter

• International study finds "worrying" levels of XDR-TB

  Results of an international study published in The Lancet show that 7% of people receiving second-line treatment for tuberculosis (TB) have extensively drug-resistant TB (XDR-TB). The investigators describe this finding as “worrying”. A total of 1278 people from eight countries were ...

  31 August 2012 | Michael Carter

• Raltegravir 800mg twice daily appears a good alternative to efavirenz for HIV-TB treatment

  Raltegravir seems to be a suitable alternative to efavirenz for HIV-TB co-infected patients while receiving TB treatment, according to 24-week results of the ANRS 12 180 REFLATE study presented at the Nineteenth International AIDS Conference (AIDS 2012) in Washington ...

  31 July 2012 | Lesley Odendal

• Novel TB combination regimen shows potent activity in randomised short-term clinical trial

  A new TB drug, PA-824, showed very potent early bactericidal activity in a randomised 14-day study in people with TB, when used in combination with the established antibiotic moxifloxacin, and pyrazinamide, an existing TB drug, according to a presentation by ...

  25 July 2012 | Theo Smart

• Co-administration of rifampicin and efavirenz does not reduce efavirenz concentrations or efficacy

  Standard dosing of efavirenz, that was not adjusted for patient weight, resulted in therapeutic efavirenz concentrations and excellent virological outcomes in patients coinfected with TB and HIV who were also taking a rifampicin-containing TB treatment, according to results from the ...

  24 July 2012 | Lesley Odendal

• Low CD4 cell count and older age associated with increased risk of TB after starting HIV therapy

  People with HIV reduce their overall risk of tuberculosis (TB) by starting antiretroviral therapy, an international team of investigators report in the online edition of Clinical Infectious Diseases. Despite this, the risk of the disease increased in the first ...

  11 April 2012 | Michael Carter

• A low CD4 cell count, weight and haemoglobin can identify which HIV-positive patients are more likely to have undiagnosed TB

  Undiagnosed tuberculosis (TB) is common among patients receiving routine HIV care in South Africa, a study published in the online edition of the Journal of Acquired Immune Deficiency Syndromes suggests, reinforcing World Health Organization guidance regarding routine screening of ...

  04 April 2012 | Michael Carter

More news

TB treatment news selected from other sources

• An Activist’s Guide to Bedaquiline (Sirturo)

  Bedaquiline (also known by its trade name, Sirturo, or as TMC207) is the first new drug from a new drug class to treat TB to be approved by the United States Food and Drug Administration (FDA) in over 40 years. This guide highlights important safety and efficacy data reported thus far and offers advocacy recommendations for activists to take forward. .

  12 March 2013 | Treatment Action Group

• In India, Fighting TB with Fingerprints

  Health specialists in India are using fingerprint technology to make sure tuberculosis sufferers receive proper treatment for the deadly lung infection.

  28 February 2013 | Voice of America

• CDC report on U.S. TB drug shortage reflects local and global challenges

  According to an article in this week’s Morbidity and Mortality Weekly Report, the 26 health departments handling about 75 percent of the United States tuberculosis caseload have confronted multidrug-resistant tuberculosis, with 21 of those departments — more than 80 percent – facing obstacles to getting the medicine necessary to treat it.

  21 January 2013 | Science Speaks

• US Food and Drug Administration approves Sirturo (bedaquiline) to treat MDR TB in adults

  The US drug licensing authority has approved the first drug to be developed for multidrug-resistant tuberculosis (MDR TB). Bedaquiline is the first new TB and antimycobacterial drug of any kind to be approved since rifabutin in 1992, and the first new class of drugs for 45 years, since rifampicin in 1967.

  02 January 2013 | FDA

• Treatment Action Group welcomes FDA review of first new tuberculosis drug in half a century

  “The decision you make today is going to affect millions of people around the world,” TAG executive director Mark Harrington said today to the FDA Center for Drug Evaluation and Research at the landmark Anti-Infective Drugs Advisory Committee Meeting.

  29 November 2012 | Treatment Action Group

• New type of TB drug deemed safe by FDA

  A tuberculosis drug under review by the FDA seems to work well in combination with other treatments while appearing to be "safe and well-tolerated," the agency said. Bedaquiline (Sirturo) could provide help in treating multi-drug resistant Mycobacterium tuberculosis, the FDA said in briefing documents released ahead of an advisory committee.

  28 November 2012 | MedPage Today

• Paper Test Could Make Drug Treatment Safer

  Researchers looking to make tuberculosis (TB) and HIV treatment safer have developed a paper-based test for drug-induced liver damage.

  19 November 2012 | Asian Scientist Magazine

• Scientists to study the role genes play in treating TB

  The University of Liverpool has been awarded funding to determine whether differences in our genes determine how patients respond to drugs used to treat Tuberculosis in Sub-Saharan Africa.

  26 October 2012 | Eurekalert Inf Dis

• Structure discovered for promising tuberculosis drug target

  Researchers at Johns Hopkins have figured out the three-dimensional shape of the protein responsible for creating unique bonds within the cell wall of the bacteria that cause tuberculosis. The bonds make the bacteria resistant to currently available drug therapies, contributing to the alarming rise of these super-bacteria throughout the world.

  26 October 2012 | Eurekalert Inf Dis

• 20 million lives saved through TB care and control

  An estimated 20 million people are alive today as a direct result of tuberculosis (TB) care and control, according to the WHO Global tuberculosis report 2012.

  17 October 2012 | WHO

More news